Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants
Sponsor: Tyra Biosciences, Inc
Summary
The purpose of this study is to evaluate the relative bioavailability of capsule and tablet formulations of TYRA-300-B01, and to evaluate the safety, tolerability, and food effect of TYRA-300-B01 tablets in healthy adult participants.
Official title: A Phase 1, Multi-cohort, Open-label Study to Evaluate the Relative Bioavailability of Capsule and Tablet Formulations of TYRA-300-B01, and to Evaluate the Safety, Tolerability, and Food Effect of TYRA-300-B01 Tablets in Healthy Adult Participants
Key Details
Gender
All
Age Range
26 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-10-16
Completion Date
2025-07
Last Updated
2025-03-26
Healthy Volunteers
Yes
Conditions
Interventions
TYRA-300-B01
TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR3.
Locations (1)
Nucleus Network
Melbourne, Victoria, Australia